Development of an efficient in vivo cell-based assay system for monitoring hepatitis C virus genotype 4a NS3/4A protease activity

Abstract

Hepatitis C virus (HCV) represents a serious worldwide healthcare problem. No protective vaccines against HCV have been developed yet due to the fact that HCV is rapidly mutable, allowing the virus to escape from the neutralizing antibodies. Understanding of HCV was initially hampered by the inability to achieve viral replication in cell culture. Given its essential roles in viral polyprotein processing and immune evasion, HCV NS3/4A protease is a prime target for antiviral chemotherapy. We aimed to establish in vivo cell-based assay system for monitoring the activity of NS3/4A protease from HCV genotype 4a, the predominant genotype in Egypt, and the Middle East. Furthermore, the developed system was used to evaluate the inhibitory potency of a series of computer-designed chemically-synthesized compounds against NS3/4A protease from HCV genotype 4a. Materials and Methods: Native as well as mutant cleavage sites to NS3/4A protease were cloned in frame into β-galactosidase gene of TA cloning vector. The target specificity of HCV NS3/4A was evaluated by coexpression of β-galactosidase containing the protease cleavage site with NS3/4A protease construct in bacterial cells. The activity of β-galactosidase was colorimetrically estimated in the cell lysate using orthonitro phenyl β-D-galactopyanoside (ONPG) as a substrate. Results and Conclusions: We successfully developed an efficient cell-based system based on the blue/white selection of bacterial cells that are able to express functional/nonfunctional β-galactosidase enzyme. Naguib Mohamed 1 Department of Biochemistry, Faculty of Science, Ain Shams University, Cairo Mohamed Mohamed 2 Department of Biochemistry, Faculty of Science, Ain Shams University, Cairo M. Ali Mohamed 3 Department of Biochemistry, Faculty of Science, Ain Shams University, Cairo Karim Amr 4 Department of Biochemistry, Faculty of Science, Ain Shams University, Cairo World Health Organization (WHO) Hepatitis C Fact Sheet, No. 164. Updated July 2017. Available from: http://www.who.int/mediacentre/factsheets/fs164/en/. [Last accessed on 2017 Dec 24]. Seeff LB. Natural history of chronic hepatitis C. Hepatology. 2002;36 (5 Suppl 1):S35-46. Smith DB, Bukh J, Kuiken C, Muerhoff AS, Rice CM, Stapleton JT, et al. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: Updated criteria and genotype assignment web resource. Hepatology 2014;59:318-27. Iles JC, Raghwani J, Harrison GLA, Pepin J, Djoko CF, Tamoufe U, et al. Phylogeography and epidemic history of hepatitis C virus genotype 4 in Africa. Virology 2014;464-465:233-43. Bartenschlager R, Ahlborn-Laake L, Yasargil K, Mous J, Jacobsen H. Substrate determinants for cleavage in cis and in trans by the hepatitis C virus NS3 proteinase. J Virol 1995;69:198-205. Kwong AD, Kim JL, Rao G, Lipovsek D, Raybuck SA. Hepatitis C virus NS3/4A protease. Antiviral Res 1999;41:67-84. Morikawa K, Lange CM, Gouttenoire J, Meylan E, Brass V, Penin F, et al. Nonstructural protein 3-4A: The Swiss army knife of hepatitis C virus. J Viral Hepat 2011;18:305-15. Tomei L, Failla C, Vitale RL, Bianchi E, De Francesco R. A central hydrophobic domain of the hepatitis C virus NS4A protein is necessary and sufficient for the activation of the NS3 protease. J Gen Virol 1996;77:1065-70. Kim JL, Morgenstern KA, Lin C, Fox T, Dwyer MD, Landro JA, et al. Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide. Cell 1996;87:343-55. Asselah T, Marcellin P. Direct acting antivirals for the treatment of chronic hepatitis C: One pill a day for tomorrow. Liver Int 2012;32(Suppl 1):88-102. Manns MP, von Hahn T. Novel therapies for hepatitis C-one pill fits all? Nat Rev Drug Discov 2013;12:595-610. McCauley JA, Rudd MT. Hepatitis C virus NS3/4a protease inhibitors. Curr Opin Pharmacol 2016;30:84-92. Pawlotsky JM. New antiviral agents for hepatitis C. F1000 Biol Rep. 2012;4:5. Lohmann V, Körner F, Koch J, Herian U, Theilmann L, Bartenschlager R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999;285:110-3. Lindenbach BD, Evans MJ, Syder AJ, Wölk B, Tellinghuisen TL, Liu CC, et al. Complete replication of hepatitis C virus in cell culture. Science 2005;309:623-6. Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, Zhao Z, et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 2005;11:791-6. Zhong J, Gastaminza P, Cheng G, Kapadia S, Kato T, Burton DR, et al. Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci U S A 2005;102:9294-9. El-Sayed SM, Ali MAM, El-Gendy BEM, Dandash SS, Issac Y, Saad R, et al. Identification of novel small molecule inhibitors against the NS3/4A protease of hepatitis C virus genotype 4a. Curr Pharm Des 2018. doi: 10.2174/1381612825666181203153835. Breiman A, Vitour D, Vilasco M, Ottone C, Molina S, Pichard L, et al. A hepatitis C virus (HCV) NS3/4A protease-dependent strategy for the identification and purification of HCV-infected cells. J Gen Virol 2006;87:3587-98. Lee JC, Chang CF, Chi YH, Hwang DR, Hsu JT. A reporter-based assay for identifying hepatitis C virus inhibitors based on subgenomic replicon cells. J Virol Methods 2004;116:27-33. Pacini L, Bartholomew L, Vitelli A, Migliaccio G. Reporter substrates for assessing the activity of the hepatitis C virus NS3-4A serine protease in living cells. Anal Biochem 2004;331:46-59. Du GX, Hou LH, Guan RB, Tong YG, Wang HT. Establishment of a simple assay in vitro for hepatitis C virus NS3 serine protease based on recombinant substrate and single-chain protease. World J Gastroenterol 2002;8:1088-93. Martinez MA, Clotet B. Genetic screen for monitoring hepatitis C virus NS3 serine protease activity. Antimicrob Agents Chemother 2003;47:1760-5. Sabariegos R, Picazo F, Domingo B, Franco S, Martinez MA, Llopis J. Fluorescence resonance energy transfer-based assay for characterization of hepatitis C virus NS3-4A protease activity in live cells Antimicrob Agents Chemother 2009;53:728-34. Mao HX, Lan SY, Hu YW, Xiang L, Yuan ZH. Establishment of a cell-based assay system for hepatitis C virus serine protease and its primary applications. World J Gastroenterol 2003;9:2474-9. Berger J, Hauber J, Hauber R, Geiger R, Cullen BR. Secreted placental alkaline phosphatase: A powerful new quantitative indicator of gene expression in eukaryotic cells. Gene 1988;66:1-10. Kakiuchi N, Nishikawa S, Hattori M, Shimotohno K. A high throughput assay of the hepatitis C virus nonstructural protein 3 serine proteinase. J Virol Methods 1999;80:77-84. Cerretani M, Di Renzo L, Serafini S, Vitelli A, Gennari N, Bianchi E, et al. A high-throughput radiometric assay for hepatitis C virus NS3 protease. Anal Biochem 1999;266:192-7. Sali DL, Ingram R, Wendel M, Gupta D, McNemar C, Tsarbopoulos A, et al. Serine protease of hepatitis C virus expressed in insect cells as the NS3/4A complex. Biochemistry 1998;37:3392-401. Vishnuvardhan D, Kakiuchi N, Urvil PT, Shimotohno K, Kumar PK, Nishikawa S. Expression of highly active recombinant NS3 protease domain of hepatitis C virus in E. coli. FEBS Lett 1997;402:209-12. Yan Y, Li Y, Munshi S, Sardana V, Cole JL, Sardana M, et al. Complex of NS3 protease and NS4A peptide of BK strain hepatitis C virus: A 2.2 A resolution structure in a hexagonal crystal form. Protein Sci 1998;7:837-47. Inoue H, Sakashita H, Shimizu Y, Yamaji K, Yokota T, Sudo K, et al. Expression of a hepatitis C virus NS3 protease-NS4A fusion protein in Escherichia coli. Biochem Biophys Res Commun 1998;245:478-82. Taremi SS, Beyer B, Maher M, Yao N, Prosise W, Weber PC, et al. Construction, expression, and characterization of a novel fully activated recombinant single-chain hepatitis C virus protease. Protein Sci 1998;7:2143-9. Howe AY, Chase R, Taremi SS, Risano C, Beyer B, Malcolm B, et al. A novel recombinant single-chain hepatitis C virus NS3-NS4A protein with improved helicase activity Protein Sci 1999;8:1332-41. Hockney RC. Recent developments in heterologous protein production in Escherichia coli. Trends Biotechnol 1994;12:456-63. Swartz JR. Advances in Escherichia coli production of therapeutic proteins. Curr Opin Biotechnol 2001;12:195-201. Mossakowska DE. Expression of nuclear hormone receptors in Escherichia coli. Curr Opin Biotechnol 1998;9:502-5. Shoji I, Suzuki T, Chieda S, Sato M, Harada T, Chiba T, et al. Proteolytic activity of NS3 serine proteinase of hepatitis C virus efficiently expressed in Escherichia coli. Hepatology 1995;22:1648-55. Steinkühler C, Tomei L, De Francesco R. In vitro activity of hepatitis C virus protease NS3 purified from recombinant Baculovirus-infected Sf9 cells. J Biol Chem 1996;271:6367-73.